HELSINKI, June 20 (Xinhua) -- A new therapy for acute lymphoblastic leukemia (ALL), the most common cancer affecting children, has been developed by Finland's Tampere University in cooperation with Harvard Stem Cell Institute.
The prognosis for the T-ALL form of leukemia when relapsed is very poor, and new treatments are urgently required. The new therapy developed by the two institutions is a combination of drugs which was found to be effective in approximately one-third of patients.
